|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:vincristine
|
|
gptkbp:activities
|
inhibits microtubule formation
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:brand
|
gptkb:Oncovin
Vincasar
|
|
gptkbp:can_be_used_with
|
gptkb:Methotrexate
gptkb:Cyclophosphamide
gptkb:Doxorubicin
Corticosteroids
|
|
gptkbp:class
|
Vinca alkaloids
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe liver disease
active infection
hypersensitivity to vincristine
|
|
gptkbp:discovered_by
|
1960s
Catharanthus roseus
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:healthcare
|
gptkb:1963
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oncovin
|
|
gptkbp:ingredients
|
gptkb:Vincristine
C46 H58 N4 O10
|
|
gptkbp:is_atype_of
|
L01 C A01
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
approximately 85 hours
|
|
gptkbp:manager
|
intravenous
intrathecal
|
|
gptkbp:marketed_as
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:origin
|
periwinkle plant
|
|
gptkbp:related_to
|
gptkb:healthcare_organization
gptkb:Wilms_tumor
Neuroblastoma
|
|
gptkbp:side_effect
|
nausea
constipation
hair loss
neuropathy
|
|
gptkbp:social_structure
|
gptkb:drug
|
|
gptkbp:treatment
|
gptkb:CHOP_regimen
gptkb:ICE_regimen
R-CHOP regimen
ABVD regimen
EPOCH regimen
Hyper-CVAD regimen
MOPP regimen
R-CHOP-14 regimen
R-ICE regimen
VAD regimen
|
|
gptkbp:type_of
|
57-22-7
|